Skip to main content

FibroBiologics, Inc.

corporate_fare Company Profile

FibroBiologics, Inc.

FBLG·NASDAQ·Life Sciences·CIK 0001958777

FibroBiologics, Inc. is a clinical-stage biotechnology company that develops and commercializes fibroblast-based therapies for chronic diseases with significant unmet medical needs. These diseases include wound healing, multiple sclerosis (MS), degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications such as thymic involution reversal using a thymic organoid. The company's most advanced product candidates are CYWC628, CYPS317, CYMS101, and CybroCell™. FibroBiologics was initially formed in April 2021 as FibroBiologics, LLC, a Texas limited liability company, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, the company changed its name to FibroBiologics, Inc. The company was formed based on intellectual property obtained from its former parent, SpinalCyte LLC (d/b/a FibroGenesis), through a patent assignment agreement and an intellectual property cross-licensing agreement. Preclinical research and development related to this intellectual property occurred under FibroGenesis prior to FibroBiologics' inception. The company's technology platform utilizes fibroblasts, which are a main cell type of connective tissue, capable of regenerating tissue and organs. While historically believed to primarily produce the extracellular matrix, fibroblasts have also demonstrated roles in immune modulation and maintaining stem cell niches, and are important in every stage of wound healing.

FibroBiologics, Inc. (NASDAQ:FBLG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for FBLG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-08, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 12 rated 8 or above. Recent SEC coverage for FBLG spans 8-K, SCHEDULE 13D, 10-Q, DEF 14A.

Recent high-impact activity:

  • FibroBiologics Sells $1.2M Convertible Debenture at 15% Discount to Peak One
  • CSO Invests $0.5M in New Private Placement as Stockholders Approve Warrant Share Issuance
  • CSO Hamid Khoja Buys $0.5M in FibroBiologics Private Placement at $1.675/Share
  • CSO's $0.5M Private Placement Signals Insider Confidence Amid Nasdaq Delisting Battle
  • FibroBiologics Wins U.S. Patent for Fibroblast Tech to Boost Islet Transplant Survival

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$18.65M
Diluted EPS
-$0.42
Op. Cash Flow
-$16.39M
Free Cash Flow
-$16.66M
Operating Income
-$16.65M
Cash & Equivalents
$4.89M
Debt / Equity
0.00×
Shares Outstanding
44.66M sh
Source: 10-K · filed 2026-03-13 · accession 0001193125-26-106216

Short Interest & Short Volume

3.12 days to cover

FINRA reported short interest of 334,123 shares in FBLG as of the October 30, 2026 settlement, a 1.1% increase from the prior period — about 3.1 days to cover at its recent average daily volume. On November 19, 2026, 70.3% of FBLG volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)334,123 shares as of October 30, 2026
Change vs prior period▲ 1.1%
Days to cover3.12 at avg daily volume of 106,998
Daily short volume (FINRA facilities)70.3% of 17,650 shares on November 19, 2026
5-day average short volume47.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for FBLG, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.

1 shelf registration

Proxy Seeks Approval for 8.4M Warrant Shares · Dilution Would Exceed 50% of Current Outstanding

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with F →
$0.7161 -13.72% today
52-week range · as of 2026-10-08 $0.62 – $10.33
Market cap
$6.44M
Volume
47.2K (0.5× avg)
3-mo avg 86.3K
Live data · 2026-11-20 20:49 UTC · Market open

show_chartPrice Chart

Loading chart...

feed FBLG - Latest Insights

FBLG
Oct 08, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $0.7161 info
Change: -$0.4139 (-37%) info
Market Cap: $6.437M info
FBLG
Sep 18, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $0.7161 info
Change: -$0.7139 (-50%) info
Market Cap: $6.437M info
FBLG
Sep 17, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.7161 info
Change: -$0.7689 (-52%) info
Market Cap: $6.437M info
FBLG
Sep 15, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $0.7161 info
Change: -$0.8318 (-54%) info
Market Cap: $6.437M info
FBLG
Aug 11, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.7161 info
Change: -$0.2339 (-25%) info
Market Cap: $6.437M info
FBLG
Jul 31, 2026, 5:34 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.700
Real-time Price: $0.7161 info
Change: +$0.0161 (+2%) info
Market Cap: $6.437M info
FBLG
Jul 31, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.700
Real-time Price: $0.7161 info
Change: +$0.0161 (+2%) info
Market Cap: $6.437M info
FBLG
Jul 31, 2026, 9:14 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.700
Real-time Price: $0.7161 info
Change: +$0.0161 (+2%) info
Market Cap: $6.437M info
FBLG
Jul 24, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.712
Real-time Price: $0.7161 info
Change: +$0.0041 (+0.58%) info
Market Cap: $6.437M info
FBLG
Jul 17, 2026, 4:31 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.8349
Real-time Price: $0.7161 info
Change: -$0.1188 (-14%) info
Market Cap: $6.437M info
FBLG
Jul 16, 2026, 4:11 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.8398
Real-time Price: $0.7161 info
Change: -$0.1237 (-15%) info
Market Cap: $6.437M info
FBLG
Jul 09, 2026, 6:05 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.8435
Real-time Price: $0.7161 info
Change: -$0.1274 (-15%) info
Market Cap: $6.437M info
FBLG
Jun 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7809
Real-time Price: $0.7161 info
Change: -$0.0648 (-8%) info
Market Cap: $6.437M info
FBLG
Jun 29, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.7949
Real-time Price: $0.7161 info
Change: -$0.0788 (-10%) info
Market Cap: $6.437M info
FBLG
Jun 26, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.7719
Real-time Price: $0.7161 info
Change: -$0.0558 (-7%) info
Market Cap: $6.437M info
FBLG
Jun 23, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.788
Real-time Price: $0.7161 info
Change: -$0.0719 (-9%) info
Market Cap: $6.437M info
FBLG
Jun 16, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.8629
Real-time Price: $0.7161 info
Change: -$0.1468 (-17%) info
Market Cap: $6.437M info
FBLG
Jun 03, 2026, 7:26 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.7161 info
Change: -$0.3639 (-34%) info
Market Cap: $6.437M info
FBLG
May 05, 2026, 5:39 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.31
Real-time Price: $0.7161 info
Change: -$0.5939 (-45%) info
Market Cap: $6.437M info
FBLG
May 05, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.7161 info
Change: -$0.7639 (-52%) info
Market Cap: $6.437M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets